Prognoses Differ Among Patients With Asymptomatic, Symptomatic Metastatic Breast Cancer
In a recent retrospective analysis, researchers found that patients with asymptomatic and symptomatic metastatic breast cancer differed in terms of subtypes, prognosis, and duration of chemotherapy.
In this study, researchers analyzed 204 patients with metastatic breast cancer (mBC), (114 asymptomatic; 90 symptomatic) to compared prognosis by breast cancer subtypes luminal (HR+/HER2-), HR+/HER2+, and triple negative (TN) (HR-/HER2-).
Patients with asymptomatic mBC had a median post-recurrence survival (PRS) or 55 months, compared to 29 months for symptomatic mBC. Patients with asymptomatic mBC also tended to have a longer overall survival. According to a multivariate analysis, independent predictors of PRS included TN, recurrence-free survival, multiple metastatic sites, and symptomatic disease.
The study authors added that “unique treatment strategy for asymptomatic or symptomatic mBC should be developed.”
Source
Kuba S, Maeda S, Minami S, et al. Post-recurrence survival in asymptomatic compared with symptomatic metastatic breast cancer: A multi center retrospective study. Abstract presented at: American Society for Clinical Oncology Annual Meeting 2022; June 3-7, 2022. Chicago, IL.
